GT201300182A - Metodo para el tratamiento de una infeccion - Google Patents

Metodo para el tratamiento de una infeccion

Info

Publication number
GT201300182A
GT201300182A GT201300182A GT201300182A GT201300182A GT 201300182 A GT201300182 A GT 201300182A GT 201300182 A GT201300182 A GT 201300182A GT 201300182 A GT201300182 A GT 201300182A GT 201300182 A GT201300182 A GT 201300182A
Authority
GT
Guatemala
Prior art keywords
treatment
composition
antico
antibiotics
water solvent
Prior art date
Application number
GT201300182A
Other languages
English (en)
Inventor
Fadil Al Alawi
Wayne Frederick Leech
Karthigeyan Nanjan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46515931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201300182A publication Critical patent/GT201300182A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE SE REFIERE A UNA COMPOSICIÓN INYECTABLE CUANDO SE UTILIZA PARA EL TRATAMIENTO DE UNA INFECCIÓN MICROBIANA EN UNA GLÁNDULA MAMARIA DE UN ANIMAL, EN EL QUE LA COMPOSICIÓN INCLUYE A) UN FÁRMACO ANTI-INFLAMATORIO NO ESTEROIDEO (AINE)B) UN ANTIBIÓTICO SELECCIONADO DE ENTRE EL GRUPO QUE CONSISTE DE UN ANTIBIÓTICO BETA LACTÁMICO Y MACRÓLIDOCARACTERIZADO PORQUE LA COMPOSICIÓN INCLUYE UN DISOLVENTE NO ACUOSO, Y EL AINE Y LOS ANTIBIÓTICOS EN LA COMPOSICIÓN SE DISUELVE EN EL DISOLVENTE NO ACUOSO.
GT201300182A 2011-01-20 2013-07-17 Metodo para el tratamiento de una infeccion GT201300182A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ588686A NZ588686A (en) 2011-01-20 2011-01-20 Injectable composition comprising an NSAID and an antibiotic in a non-aqueous solvent for treating a microbial infection in a mammary gland

Publications (1)

Publication Number Publication Date
GT201300182A true GT201300182A (es) 2014-07-28

Family

ID=46515931

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300182A GT201300182A (es) 2011-01-20 2013-07-17 Metodo para el tratamiento de una infeccion

Country Status (15)

Country Link
KR (1) KR101905173B1 (es)
CN (1) CN103327984B (es)
AU (1) AU2012207698A1 (es)
BR (1) BR112013018557B1 (es)
CL (1) CL2013002086A1 (es)
CO (1) CO6801732A2 (es)
CR (1) CR20130401A (es)
GT (1) GT201300182A (es)
IL (1) IL227540A (es)
MX (1) MX353876B (es)
NI (1) NI201300063A (es)
NZ (1) NZ588686A (es)
PE (1) PE20140035A1 (es)
WO (1) WO2012099479A1 (es)
ZA (1) ZA201305780B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2995297A1 (fr) * 2014-09-09 2016-03-16 Ceva Sante Animale Compositions parentérales et leurs utilisations
AR102172A1 (es) * 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
CN105663037A (zh) * 2016-01-27 2016-06-15 成都乾坤动物药业有限公司 一种阿莫西林溶液剂及其制备方法和用途
CN112472667B (zh) * 2019-08-23 2022-11-15 北京欧博方医药科技有限公司 一种维他昔布长效注射液及其制备方法和应用
CN111035614B (zh) * 2019-12-20 2024-02-02 北京喜禽药业有限公司 一种高含量土霉素注射液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787568B1 (en) * 2000-11-27 2004-09-07 Phoenix Scientific, Inc. Antibiotic/analgesic formulation and a method of making this formulation
CN1297319C (zh) * 2003-09-22 2007-01-31 王玉万 以硅油为介质制备含抗微生物药物的制剂
EP1677781A4 (en) * 2003-10-29 2008-11-19 Idexx Lab Inc SALTS OF PHARMACOLOGICALLY ACTIVE COMPOUNDS
DE102004025324A1 (de) * 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
KR101905173B1 (ko) 2018-11-28
WO2012099479A1 (en) 2012-07-26
BR112013018557B1 (pt) 2021-11-03
MX2013008407A (es) 2013-09-26
KR20140012646A (ko) 2014-02-03
CN103327984B (zh) 2016-08-17
NZ588686A (en) 2013-07-26
NI201300063A (es) 2014-05-23
AU2012207698A1 (en) 2013-04-18
ZA201305780B (en) 2014-04-30
IL227540A0 (en) 2013-09-30
BR112013018557A2 (pt) 2016-11-22
CR20130401A (es) 2014-02-04
CL2013002086A1 (es) 2014-07-25
IL227540A (en) 2017-12-31
CO6801732A2 (es) 2013-11-29
MX353876B (es) 2018-02-01
PE20140035A1 (es) 2014-02-16
CN103327984A (zh) 2013-09-25

Similar Documents

Publication Publication Date Title
CL2019001551A1 (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
CO2019009258A2 (es) Administración rápida y controlada de composiciones con efectos séquito restaurados
CR20140541A (es) Formulaciones farmacéuticas tópicas no acuosas
CL2009000178A1 (es) Composicion que comprende un anticuerpo contra el dominio ii de her2, sus variantes acidas, secuencias que comprenden las cadenas livianas y pesadas de este; formulacion farmaceutica que comprende dicho anticuerpo y uso de este para cancer her2 positivo.
UY34649A (es) Compuestos heterobicíclicos
UY33775A (es) Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
GT201300182A (es) Metodo para el tratamiento de una infeccion
DOP2016000253A (es) Nuevos compuestos
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
ES2552754T1 (es) Formulaciones de daptomicina y usos de la misma
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CU20160072A7 (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
DOP2016000007A (es) Pirazolpiridinas sustituidas
UY36373A (es) Compuestos para usarse en el tratamiento antihelmíntico
CL2013003111A1 (es) Metodo para la preparacion de una composicion farmaceutica que contiene un transportador de oxigeno purificado y termicamente estable, que contiene el transportador de oxigeno hemoglobina, donde la hemoglobina incluye a hemoglobina polimerica entrecruzada.
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
BR112017008033A2 (pt) composição farmacêutica para administração oral e respectivo processo de preparação
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
CY1120016T1 (el) Φαρμακοτεχνικες μορφες οξικης κασποφουνγκινης
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia